Abstract
A duplexed, functional multiaddition high throughput screen and subsequent optimization effort identified the first orally bioavailable and CNS penetrant glucagon-like peptide-1 receptor (GLP-1R) noncompetitive antagonist. Antagonist 5d not only blocked exendin-4-stimulated insulin release in islets but also lowered insulin levels while increasing blood glucose in vivo.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Animals
-
Blood Glucose / analysis
-
Blood Glucose / metabolism
-
Cells, Cultured
-
Central Nervous System / drug effects
-
Central Nervous System / metabolism
-
Glucagon-Like Peptide-1 Receptor / antagonists & inhibitors*
-
Glucagon-Like Peptide-1 Receptor / metabolism
-
Halogenation
-
Humans
-
Insulin / blood
-
Insulin / metabolism
-
Islets of Langerhans / drug effects
-
Islets of Langerhans / metabolism
-
Male
-
Pyrimidines / administration & dosage
-
Pyrimidines / chemistry*
-
Pyrimidines / pharmacokinetics
-
Pyrimidines / pharmacology*
-
Rats, Sprague-Dawley
Substances
-
Blood Glucose
-
Glucagon-Like Peptide-1 Receptor
-
Insulin
-
Pyrimidines